Kristian Sandberg

Platform Co-Director, Uppsala University

Drug Discovery and Development

Key publications

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.
Luttens, A., Gullberg, H., Abdurakhmanov, E., Vo, D. D., Akaberi, D., Talibov, V. O., . . . Carlsson, J. (2022).
Journal of the American Chemical Society, 144(7), 2905-2920

Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci.
Drobin, K., Assadi, G., Hong, M.-G., Andersson, E., Fredolini, C., Forsström, B., . . . Halfvarson, J. (2019).
Inflammatory Bowel Diseases, 25(2), 306-316

Open for collaboration: an academic platform for drug discovery and development at SciLifeLab.
Arvidsson, P. I., Sandberg, K. & Forsberg-Nilsson, K. (2016).
Drug Discovery Today, 21(10), 1690-1698

Tryptophan Metabolism Along the Kynurenine Pathway Downstream of Toll-like Receptor Stimulation in Peripheral Monocytes.
Orhan, F., Bhat, M., Sandberg, K., Stahl, S., Piehl, F., Svensson, C., . . . Schwieler, L. (2016).
Scandinavian Journal of Immunology, 84(5), 262-271

Positive Modulation of the Glycine Receptor by Means of Glycine Receptor-Binding Aptamers.
Shalaly, N. D., Aneiros, E., Blank, M., Mueller, J., Nyman, E., Blind, M., . . . Sandberg, K. (2015).
Journal of Biomolecular Screening, 20(9), 1112-1123

Identification of unique and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries.
Akaberi, D., Pourghasemi Lati, M., Krambrich, J., Berger, J., Turunen, P., Gullberg, H., . . . Lennerstrand, J.

My research

Research interest includes drug discovery & autoimmune, infectious and inflammatory diseases including neuroinflammation. In addition to Uppsala University am I affiliated to Karolinska Institutet, Dept. Phys. and Pharmacol, Sophie Erhardt team; Toleranzia AB (board member) and; Lipum AB (board member).

Last updated: 2024-12-09

Content Responsible: Josefin Lundgren Gawell(josefin.lundgren.gawell@scilifelab.se)